Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene.

Heterozygous activating mutations of KCNJ11 (Kir6.2) are the most common cause of permanent neonatal diabetes mellitus (PNDM) and several cases have been successfully treated with oral sulfonylureas. We report on the attempted transfer of insulin therapy to glibenclamide in a 4-year old child with PNDM and DEND syndrome, bearing a C166Y mutation in KCNJ11. An inpatient transition from subcutaneous NPH insulin (0.2 units/kg/d) to oral glibenclamide (1 mg/kg/d and 1.5 mg/kg/d) was performed. Glucose and C-peptide responses stimulated by oral glucose tolerance test (OGTT), hemoglobin A1c levels, the 8-point self-measured blood glucose (SMBG) profile and the frequency of hypoglycemia episodes were analyzed, before and during treatment with glibenclamide. Neither diabetes control nor neurological improvements were observed. We concluded that C166Y mutation was associated with a form of PNDM insensitive to glibenclamide.

[1]  B. Shields,et al.  Insulin Mutation Screening in 1,044 Patients With Diabetes , 2008, Diabetes.

[2]  F. Cadario,et al.  The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy. , 2008, The Journal of clinical endocrinology and metabolism.

[3]  A. Hattersley,et al.  Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[4]  J. Bryan,et al.  Neonatal diabetes mellitus. , 2008, Endocrine reviews.

[5]  F. Crispim,et al.  Sulfonylrea Treatment in Permanent Neonatal Diabetes Due to G53D Mutation in the KCNJ11 Gene , 2007, Diabetes Care.

[6]  F. Ashcroft,et al.  Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11 , 2007, Nature Clinical Practice Neurology.

[7]  Y. Makita,et al.  Molecular basis of neonatal diabetes in Japanese patients. , 2007, The Journal of clinical endocrinology and metabolism.

[8]  K. Shimomura,et al.  A novel mutation causing DEND syndrome , 2007, Neurology.

[9]  C. Bellanné-Chantelot,et al.  Infantile Spasms as an Epileptic Feature of DEND Syndrome Associated With an Activating Mutation in the Potassium Adenosine Triphosphate (ATP) Channel, Kir6.2 , 2007, Journal of child neurology.

[10]  F. Ashcroft,et al.  Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. , 2007, American journal of human genetics.

[11]  M. Polak,et al.  Neonatal diabetes mellitus : a disease linked to multiple mechanisms , 2015 .

[12]  C. Nichols,et al.  An ATP-Binding Mutation (G334D) in KCNJ11 Is Associated With a Sulfonylurea-Insensitive Form of Developmental Delay, Epilepsy, and Neonatal Diabetes , 2007, Diabetes.

[13]  A. Hattersley,et al.  Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene , 2006, Diabetologia.

[14]  R. Scharfmann,et al.  Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. , 2006, The New England journal of medicine.

[15]  F. Ashcroft,et al.  Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. , 2006, The New England journal of medicine.

[16]  A. Hattersley,et al.  KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features , 2006, European Journal of Human Genetics.

[17]  A. Hattersley,et al.  Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype , 2006, Diabetologia.

[18]  F. Ashcroft,et al.  Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. , 2005, Diabetes.

[19]  M. Sperling.  Neonatal diabetes mellitus: from understudy to center stage , 2005, Current opinion in pediatrics.

[20]  S. Ellard,et al.  The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation , 2005, Diabetologia.

[21]  A. Hattersley,et al.  High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. , 2005, Diabetes care.

[22]  F. Ashcroft,et al.  Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  B. Glaser,et al.  Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. , 2004, The Journal of clinical endocrinology and metabolism.

[24]  A. Hattersley,et al.  Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. , 2004, Diabetes.

[25]  F. Ashcroft,et al.  Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. , 2004, The New England journal of medicine.

[26]  André F. Reis,et al.  Patologia molecular do receptor de sulfoniluréia (SUR1) , 2000 .

[27]  F. Ashcroft,et al.  Molecular Analysis of ATP-sensitive K Channel Gating and Implications for Channel Inhibition by ATP , 1998, The Journal of general physiology.

[28]  I. Temple,et al.  Aetiopathology and genetic basis of neonatal diabetes , 1997, Archives of disease in childhood. Fetal and neonatal edition.

[29]  K. E. von Mühlendahl,et al.  Long-term course of neonatal diabetes. , 1995, The New England journal of medicine.

[30]  K. Shimomura,et al.  The K(ATP) channel and neonatal diabetes. , 2009, Endocrine journal.

[31]  Stephen O’Riordana,et al.  Insulin mutation screening in 1 , 044 patients with diabetes : mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood , 2008 .

[32]  K. Kunjilwar,et al.  Toward understanding the assembly and structure of KATP channels. , 1998, Physiological reviews.